How has been the historical performance of the Trident Texofab?

Jun 10 2025 10:38 PM IST
share
Share Via
Trident Texofab has shown steady growth in net sales and profit from March 2021 to March 2025, with net sales increasing from Rs 49.93 crore to Rs 122.06 crore, while total expenditure also rose, impacting operating profit. The company's earnings per share improved significantly, reaching Rs 1.85 in March 2025, despite rising costs and liabilities.
Answer:
The historical performance of Trident Texofab shows a steady growth in net sales and profit over the years, with significant fluctuations in costs and margins.

Breakdown:
Trident Texofab's net sales have increased from Rs 49.93 crore in March 2021 to Rs 122.06 crore in March 2025, reflecting a consistent upward trend. The total operating income followed a similar pattern, rising from Rs 84.29 crore in March 2022 to Rs 122.06 crore in March 2025. However, total expenditure has also risen, from Rs 47.05 crore in March 2021 to Rs 116.58 crore in March 2025, impacting the operating profit, which peaked at Rs 8.78 crore in March 2025 after fluctuating in previous years. The profit before tax showed variability, reaching Rs 2.58 crore in March 2025, while the profit after tax increased to Rs 2.51 crore in the same period. The company’s earnings per share (EPS) improved to Rs 1.85 in March 2025, up from Rs 0.35 in March 2021. On the balance sheet, total liabilities rose from Rs 47.04 crore in March 2019 to Rs 81.90 crore in March 2024, with total assets also increasing correspondingly. The cash flow from operating activities showed a positive trend, reaching Rs 2.00 crore in March 2024, indicating improved operational efficiency. Overall, Trident Texofab has demonstrated growth in sales and profitability, albeit with rising costs and liabilities.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Why is Trident Texofab falling/rising?
Dec 12 2025 01:10 AM IST
share
Share Via
Is Trident Texofab overvalued or undervalued?
Dec 05 2025 08:41 AM IST
share
Share Via
Is Trident Texofab technically bullish or bearish?
Dec 04 2025 08:47 AM IST
share
Share Via
How has been the historical performance of Trident Texofab?
Dec 03 2025 10:55 PM IST
share
Share Via
Is Trident Texofab overvalued or undervalued?
Nov 19 2025 08:10 AM IST
share
Share Via